EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSFCAG00000012729
Gene Symbol: ATP1A3
5 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 4

Ensembl ID : ENSFCAG00000005397
Gene Symbol: ATP1A4
5 Cross references
571 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSFCAG00000009332
Gene Symbol: ATP1B1
5 Cross references
288 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSFCAG00000009622
Gene Symbol: ATP1B2
5 Cross references
269 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSFCAG00000030431
Gene Symbol: ATP1B3
5 Cross references
296 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSFCAG00000018078
Gene Symbol: ATR
5 Cross references
207 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSFCAG00000030995
Gene Symbol: AXL
3 Cross references
198 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSFCAG00000012847
Gene Symbol: BRAF
5 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSFCAG00000029552
Gene Symbol: BCL2
5 Cross references
228 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSFCAG00000025748
Gene Symbol: BCL2L1
3 Cross references
289 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSFCAG00000040864
Gene Symbol: BCL2L10
5 Cross references
129 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSFCAG00000040747
Gene Symbol: BCL2L2
5 Cross references
64 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).